Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26707720 | 0.84 | CACNA1G (0.41) | HRH3CYP2D6KCNH2ALDH1A1KDM4E | |
| SCHEMBL23594368 | 0.83 | ALDH1A1 (0.34) | HRH3ALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL24926567 | 0.82 | HSD11B1 (0.46) | ALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL23729438 | 0.82 | HRH3 (0.40) | HRH3CYP2D6ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL21946674 | 0.81 | HRH3 (0.40) | HRH3CYP2D6KCNH2ALDH1A1KDM4E | |
| SCHEMBL23594109 | 0.81 | ALDH1A1 (0.36) | ALDH1A1KDM4E | |
| SCHEMBL21946394 | 0.80 | HRH3 (0.39) | HRH3CYP2D6KCNH2ALDH1A1KDM4E | |
| SCHEMBL24926159 | 0.80 | ALDH1A1 (0.33) | ALDH1A1KDM4E | |
| SCHEMBL24926114 | 0.80 | HRH3 (0.41) | HRH3CYP2D6KCNH2ALDH1A1KDM4E | |
| SCHEMBL16132779 | 0.79 | HRH3 (0.44) | HRH3CYP2D6KCNH2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | HRH3 3674/4885CYP2D6 3589/4885KCNH2 4713/4885 |
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | HRH3 3635/4885CYP2D6 3775/4885KCNH2 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.